Mostrando 10 resultados de: 13
Filtros aplicados
Publisher
Clinical Cancer Research(3)
Frontiers in Oncology(2)
Journal of Immunotherapy(2)
Seminars in Oncology(2)
Clinical and Translational Immunology(1)
Área temáticas
Enfermedades(13)
Medicina y salud(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Microorganismos, hongos y algas(1)
Origen
scopus(13)
Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer
ArticleAbstract: An epidermal growth factor (EGF) vaccine was given before and after standard first line chemotherapyPalabras claves:cancer vaccine, EGF, NSCLCAutores:Bárbara Wilkinson, Carmen Elena Viada, Fleites G., González G., González M.J., Lage Davila A., Leonard I., Mazorra Z., Neninger Vinageras E., Pereda S., Tania Crombet, Verdecia B.G.Fuentes:scopusAugmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusAn anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusA Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusA randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusCIMAvax-EGF: Toward long-term survival of advanced NSCLC
ReviewAbstract: Lung cancer remains one of the leading causes of cancer-related deaths. Non–small cell lung cancer (Palabras claves:cancer vaccine, CIMAvax-EGF, Clinical trial, EGF, Epidermal growth factor receptor, immunotherapy, non–small cell lung cancerAutores:Camilo Rodríguez, Carmen Elena Viada, Lage Davila A., Mazorra Z., Neninger Vinageras E., Saavedra Hernández D., Tania CrombetFuentes:scopusEffective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
ArticleAbstract: Purpose: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non-small-celPalabras claves:Autores:Carmen Elena Viada, De La Torre A.V., García Verdecia B., González G., Lage Davila A., Leonard I., Martínez R., Mazorra Z., Neninger Vinageras E., Tania CrombetFuentes:scopusNimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusImmunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients
ArticleAbstract: Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A contPalabras claves:Breast Cancer, cancer vaccine, Clinical trial, Ganglioside, immunotherapy, NeuGcGM3, patientsAutores:Cardoso J., Carmen Elena Viada, Carr A., De La Torre A.V., Díaz R., Fernandez L.E., Macías A.E., Marinello P., Mazorra Z., Mulens V., O'Farrill M., Pérez R., Rodríguez R., Saurez G., Tania CrombetFuentes:scopusImmunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy
ArticleAbstract: This study aimed to investigate the immunogenicity of a cancer vaccine consisting of the NeuGcGM3 gaPalabras claves:adjuvant therapy, Breast Cancer, cytotoxic antibodies, Ganglioside, NeuGcGM3, VaccineAutores:Curbelo I., Estevez A., Fernandez L.E., Gonzalez Z., Luaces P.L.o., Mazorra Z., Mulens V., Pérez K., Rubio M.C., Tania Crombet, Valdes-Zayas A., Vega A.M.Fuentes:scopus